Loading...
•
Mar 31, 2023
Aadi Bioscience Q1 2023 Earnings Report
Aadi Bioscience announced financial results and operational update for the first quarter 2023.
Key Takeaways
Aadi Bioscience reported total revenue of $5.9 million from FYARRO® sales in Q1 2023, with a net loss of $15.2 million. The company is progressing with the PRECISION 1 tumor agnostic trial and expects an interim analysis by the end of 2023. They believe they are operating from a position of strength with solid cash balances into 2025.
Total revenue resulting from sales of FYARRO was $5.9 million in the first quarter 2023.
PRECISION 1 trial is enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented.
Cash, cash equivalents and short-term investments as of March 31, 2023 were $151.2 million.
Net loss for the three months ended March 31, 2023 was $15.2 million.
Aadi Bioscience
Aadi Bioscience
Forward Guidance
Aadi Bioscience expects to fund operations into 2025 based on current plans.